Post-Traumatic Stress Disorder Therapy Market, By Class of Drugs (Antidepressants, Anti-Anxiety Drugs, and Other Drug Classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI260219 | Publish Date: March 2024 | No. of Pages: 178

Global PostTraumatic Stress Disorder Therapy Overview

Post-Traumatic Stress Disorder Therapy Market was valued at US$ 2.7 Billion in 2024 and is projected to grow at a CAGR of 5% to reach US$ 4.5 Billion by 2034.

[PDF] Post-traumatic stress disorder (PTSD) is a mental health condition that gets in an active form by a traumatic event. It is either witnessed to experience natural disaster, critical accidents, sexual violence, etc. PTSD could occur to the population of any age group. Some of the major symptoms of PTSD are intrusive memories, avoidance, negative thoughts, mood swings, etc. Antidepressants, anti-anxiety medications, fluoxetine are some of the common drugs given by doctors.     

The increase in product launches, collaborations and partnerships within the industries for the development of drugs are some of the key factors that are expected to drive the growth of the global post-traumatic stress disorder treatment market. Increase in the number of clinical trials for post-traumatic stress disorder, rising R&D activities for the novel therapies and drugs is expected to drive the Post-Traumatic Stress Disorder Therapy Market growth in future

Global PostTraumatic Stress Disorder Therapy Dynamics

Growing awareness about mental health

Rising prevalence of PTSD occur due to traumatic events such as natural disaster, terrorist attacks, etc. which are some of the major factors that drive the PTSD treatment. Increase awareness on mental health and the value for the treatments for mental health are one of the main factors that is driving the demand for PTSD treatment and hence boosting the growth of the market. The new advancements and innovative therapies for the PTSD treatment such as virtual reality therapy are also expected to boost the growth of the target market.

For instance, on May 2023, according to The Economic Times, Mental Health Awareness week (MHAW) held a mental health awareness program that ran Mondays to Sundays to ensure that each and every individual should aware of mental health condition and how to seek support. MHAW surveyed mental health conditions of UK population and found out that one in ten UK adults feel hopeless about their financial conditions and the rest people have experienced general anxiety and stress.

Availability of treatments and therapies

One of a help or support an individual can seek is psychotherapy. It is a type of talk therapy in which an individual talk about their problems, strengths, weaknesses to psychiatrist in order to seek guidance and that helped many people with PTSD. There have been several types of psychotherapy which includes cognitive behavioral therapy (CBT), prolonged exposure therapy and eye movement desensitization and reprocessing (EMDR). Medication can also be used as a support that can help to manage symptoms of PTSD like depression, anxiety or insomnia. Self-help strategies would be one of the best ways to helps someone who is suffering from mental illness to manage symptoms of PTSD.

For instance, in October 2020, Jazz Pharmaceuticals company and SpringWorks Therapeutics, Inc., a biopharmaceutical company which is solely dedicated in developing and commercializing life changing medicines that transforms lives of patients. They have introduced an innovative approach to treat PTSD with a different mechanism of action that has the ability to address multiple core symptoms of the disease that includes extinction, anxiety, etc.

Restrains:

One of the major drawbacks of the global post-traumatic stress disorder treatment market is a stigma related with mental illness that includes PTSD that can be a hinderance from seeking help and accessing treatments. Individual suffering from PTSD faced many problems to access the treatments such as limited number of mental health professionals, lack of insurance coverage and long waiting time on the site of appointments.

Furthermore, August 2029, according to the Association of American Medical Colleges (AAMC) One out of every 5 people in the United States had a mental illness. 40% of adults reported symptoms of anxiety or depression, yet the United States does not have nearly enough mental health professionals to treat everyone who is suffering from mental health. Within a few years, the country will be short between 14,280 and 31,109 psychiatrists. In addition to the problem there is a gap for accessing the mental health treatments among some populations, especially for those in rural areas. 

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global PostTraumatic Stress Disorder Therapy Segmentation

 

Post-Traumatic Stress Disorder Therapy Market is segmented based on Class of drugs and Region.

Class of drugs Insight

On the basis of Class of Drugs, Post-Traumatic Stress Disorder Therapy Market is segmented into antidepressants, anti-anxiety drugs, and other drug classes. Other drug classes are further bifurcated into alpha-1 & alpha-2 receptor antagonists, atypical antipsychotics, and anticonvulsants. Antidepressants class of drugs segment is expected to dominate the target market growth due to the large number of FDA approval of selective serotonin reuptake inhibitors (SSRI’s) such as Zoloft (sertraline) and Paxil (paroxetine).

Regional Insights:

On the basis of region, the Post-Traumatic Stress Disorder Therapy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing prevalence of post-traumatic stress disorder, increased research and development activities, presence of strong and established market competitors in this region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 – 2034

Market Segmentation

By Class of drugs - antidepressants, anti-anxiety drugs, and other drug classes. Other drug classes (alpha-1 & alpha-2 receptor antagonists, atypical antipsychotics, and anticonvulsants).

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 – 2034 For the purpose of this study, has segmented the Post-Traumatic Stress Disorder Therapy Market report based on Class of drugs and Region:

Post-Traumatic Stress Disorder Therapy Market, By Class of drugs:

  • Antidepressants
  • Anti-anxiety drugs
  • Other drug classes (alpha-1 & alpha-2 receptor antagonists, atypical antipsychotics, and anticonvulsants).

Post-Traumatic Stress Disorder Therapy Market, By Region:

  • North America
    • Middle East & Africa
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
      • U.S.
      • Canada

Global PostTraumatic Stress Disorder Therapy Key Players

The key players operating the Post-Traumatic Stress Disorder Therapy Market includes, GlaxoSmithKlineplc, Pfizer, Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corp., Azevan Pharmaceuticals, Inc., Baylor Research Institute, Inc., Synchroneuron, Inc., Tonix Pharmaceuticals Holding Corp., Marinus Pharmaceuticals, Inc., and Nanotherapeutics, Inc.

Global PostTraumatic Stress Disorder Therapy Company Profile

  • GlaxoSmithKline plc*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer, Inc.
  • Neurocrine Biosciences. Inc.
  • Novartis Pharmaceuticals Corp.
  • Azevan Pharmaceuticals, Inc.
  • Baylor Research Institute, Inc.
  • Synchroneuron, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Marinus Pharmaceuticals, Inc.
  • Nanotherapeutics, Inc.

“*” marked represents similar segmentation in other categories in the respective section

Recent Development:

  • In November 2019, Bionomics limited, it is a global clinical stage biopharmaceutical company announced that U.S Food and Drug Administration (FDA) granted Fast Track designation for the BNC210 development program. BNC210 is an anxiolytic drug that acts as a negative allosteric modulation of the α7-nicotinic acetylcholine receptor. This program helped in the treatment of post-traumatic stress disorder (PTSD) and other trauma related and stressor-related disorder.
  • In January 2022, Mydecine Innovation Group Inc. has partnered with Combat Stress which is a leading charity aiding veteran’s mental health in the United Kingdom, and the King’s College London for treating the post-traumatic stress disorder (PTSD) by using Psychedelic-assisted psychotherapy. This innovation focuses on intense debates on the current diagnostics and explanations for mental disorders. Psychedelic therapy is a type of psychiatric process that involves the ingestion of psychedelic substance during psychotherapeutic process combined with talk therapy.

Global PostTraumatic Stress Disorder Therapy Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Class of Drugs
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Post-Traumatic Stress Disorder Therapy Market, By Class of Drugs
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Antidepressants
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Anti-Anxiety Drugs
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Other drug classes (alpha-1 & alpha-2 receptor antagonists, atypical antipsychotics, and anticonvulsants)
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  6. Post-Traumatic Stress Disorder Therapy   Market, By Region, 2022 – 2032, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Class of Drugs, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Class of Drugs, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Class of Drugs, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Class of Drugs, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Class of Drugs, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles
  • GlaxoSmithKline plc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Neucrine Biosciences. Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis Pharmaceuticals Corp.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Azevan Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Baylor Research Institute, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Synchroneuron, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Tonix Pharmaceuticals Holdings Corp.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Marinus Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Nanotherapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The Post-Traumatic Stress Disorder Therapy Market is segmented into Class of drugs and Region.

Post-Traumatic Stress Disorder Therapy Market is driven by factors like growing awareness on mental health and availability of treatments and therapies.

By region, the Post-Traumatic Stress Disorder Therapy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.

The key players operating the Post-Traumatic Stress Disorder Therapy Market includes, GlaxoSmithKlineplc, Pfizer, Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corp., Azevan Pharmaceuticals, Inc., Baylor Research Institute, Inc., Synchroneuron, Inc., Tonix Pharmaceuticals Holding Corp., Marinus Pharmaceuticals, Inc., and Nanotherapeutics, Inc.

Post-Traumatic Stress Disorder Therapy Market was valued at US$ 2.7 Billion in 2024 and is projected to grow at a CAGR of 5% to reach US$ 4.5 Billion by 2034.